Coverage/LLYAnalysis vnull ·

Eli Lilly

LLY·NYSEPharmaceuticals

Price

USD 1030.40

Quality Score

0/40

Rating

NEUTRAL

Current Price

USD 1030.40

Fair Value Range

–

Perception Gap

–

Last Updated

–

Perception Gap Signal

Actual Quality Score0.0/40

Perceived Quality Score0.0/40

Gap (Actual minus Perceived)

Signal within expected range

0.00

Signal Scorecard

Composite factor model · /40

Business Model

0/5

Management & Alignment

0/5

Client Quality

0/5

Organic Growth

0/5

Earnings Quality

0/5

Balance Sheet

0/5

Structural Risk

0/5

Valuation

0/5

Valuation

Interactive DCF

Stress-test the valuation — adjust assumptions to see implied value and what growth the market is pricing in

FCF / Share (USD)

trailing 12m free cash flow per diluted share

Growth rate yr 1–512%

Growth rate yr 6–107%

WACC9.0%

Terminal multiple20x

Enter FCF/share above to run the model

Find it in the company's latest annual report or financial data provider

Overall Verdict & Actionable Conclusion

This company presents a complex risk-reward profile. The qualitative moat is real, but the quantitative evidence does not yet support the valuation implied by the current price. A full verdict requires weighing the organic growth trajectory against the acquisition-inflated earnings picture. Our full actionable conclusion is available to intelligence tier subscribers.

Intelligence tier required

Get Full Access